Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Anna Couturier"'
Publikováno v:
Mcwhirter, L, Smyth, H, Hoeritzauer, I, Couturier, A, Stone, J & Carson, A J 2022, ' What is brain fog? ', Journal of Neurology, Neurosurgery & Psychiatry, pp. jnnp-2022-329683 . https://doi.org/10.1136/jnnp-2022-329683
BackgroundThe term ‘brain fog’ is increasingly used colloquially to describe difficulties in the cognitive realm. But what is brain fog? What sort of experiences do people talk about when they talk about brain fog? And, in turn, what might this t
Publikováno v:
Regenerative Medicine. 14:1137-1150
Aim: This study examines online enquiries received by two prominent stem cell science initiatives operating in different geographical jurisdictions. Materials & methods: Combined quantitative and qualitative analysis undertaken of internet-based quer
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 93:e3.18
ObjectivesThe term ‘brain fog’ is increasingly used in social and other media. But what is brain fog? What sort of experiences do people talk about when they talk about brain fog? And, in turn, what might this tell us about potential underlying p
Publikováno v:
SSCI
On October 1st, 2019 in response to critique from patient advocates and the medical community, Google explicitly prohibited promotion of unproven stem cell and gene therapy treatments on their platform in order to protect users from rising direct-to-
Publikováno v:
Erikainen, S, Couturier, A & Chan, S 2020, ' Marketing Experimental Stem Cell Therapies in the UK: Biomedical Lifestyle Products and the Promise of Regenerative Medicine in the Digital Era ', Science as Culture, vol. 29, no. 2, pp. 219-244 . https://doi.org/10.1080/09505431.2019.1656183
Science as Culture
Science as Culture
Stem cell research has attracted much public and biomedical anticipation centred on the possibility of using stem cells to treat various diseases and conditions, but the number of evidence-based therapies is currently limited. Numerous commercial dir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bba9b751dde0fb345e2e0e0c7dba5cd
https://hdl.handle.net/20.500.11820/abc2c5a5-c6f5-432b-b242-78140df78669
https://hdl.handle.net/20.500.11820/abc2c5a5-c6f5-432b-b242-78140df78669
Bortezomib-dexamethasone is widely used for relapsed myeloma in routine clinical practice, but comparative data versus single-agent bortezomib are lacking. This retrospective analysis compared second-line treatment with bortezomib-dexamethasone and b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1fda2443cc6dfc768a743ff324af5bbd
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2953943
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2953943